← Back to Clinical Trials
Recruiting NCT07256522

NCT07256522 Comparative Evaluation of Finger Splint, Paraffin, and Peloidotherapy Interventions in the Management of Trigger Finger

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07256522
Status Recruiting
Phase
Sponsor Konya Beyhekim Training and Research Hospital
Condition Trigger Finger
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-12-15
Primary Completion 2027-01-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Finger orthosisParaffin bathPeloidotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-12-15 with a primary completion date of 2027-01-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients aged 18-75 years who present with trigger finger to a tertiary rehabilitation hospital and agree to participate will be included in the study. Participants will be randomly allocated into three groups using block randomization. The first group will use a static finger splint that blocks the proximal interphalangeal joint for 6 weeks, along with a home exercise program. The second group will receive paraffin bath therapy, and the third group will receive peloidotherapy, both in combination with home exercises. All patients will receive education about the disease and activity modification. The finger joint-restricting splint and exercises will be applied for 6 weeks. Evaluations will be conducted at baseline, at the end of the 3rd week, and at the end of the 6th week by a blinded assessor. No analgesic or anti-inflammatory medication will be permitted during the study, and patients will be instructed to avoid using analgesics within 24 hours prior to each assessment.

Eligibility Criteria

Inclusion Criteria: * Being between 18 and 75 years of age and willing to participate in the study * Having a diagnosis of idiopathic single trigger finger, Grade 2-3 Exclusion Criteria: * Patients with triggering in more than one finger * Patients with triggering at the A3 pulley or with Grade 1 or Grade 4 trigger finger * Patients with thumb (pollex) trigger finger * Patients who have undergone any injection or interventional procedure (release surgery) for trigger finger within the past 6 months * Patients who have received physical therapy for the hand within the past 6 months * Patients currently using corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs) * Patients with inflammatory or autoimmune rheumatologic diseases such as rheumatoid arthritis, systemic lupus erythematosus, gout, or psoriatic arthritis * Patients with other musculoskeletal disorders (e.g., carpal tunnel syndrome, de Quervain's tenosynovitis, symptomatic hand osteoarthritis, or Dupuytren's contracture) or neurological diseases (e.g., stroke-related hemiparesis, spinal cord injury, brachial plexus injury, multiple sclerosis, or Parkinsonism) affecting the same hand * Patients with musculoskeletal disorders causing pain and/or limitation in the proximal upper extremity on the affected side (e.g., periarthritis, lateral epicondylitis, mononeuropathy, or radiculopathy) * Patients with significant metabolic diseases (e.g., hypothyroidism, Cushing's syndrome, or uncontrolled diabetes) * Patients with any condition that may interfere with treatment, such as open wounds, rashes, local infections, or active malignant disease of the hand * Patients with a history of hand trauma (chronic or repetitive) * Patients unwilling to complete the self-assessment questionnaires either independently or with assistance * Pregnant women

Contact & Investigator

Central Contact

Ramazan Yilmaz, Assoc Prof (MD)

✉ drramazanyilmaz@yahoo.com

📞 +905556232674

Principal Investigator

Ramazan Yilmaz, Assoc Prof

PRINCIPAL INVESTIGATOR

Konya Beyhekim Training and Research Hospital

Frequently Asked Questions

Who can join the NCT07256522 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Trigger Finger. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07256522 currently recruiting?

Yes, NCT07256522 is actively recruiting participants. Contact the research team at drramazanyilmaz@yahoo.com for enrollment information.

Where is the NCT07256522 trial being conducted?

This trial is being conducted at Konya, Turkey (Türkiye).

Who is sponsoring the NCT07256522 clinical trial?

NCT07256522 is sponsored by Konya Beyhekim Training and Research Hospital. The principal investigator is Ramazan Yilmaz, Assoc Prof at Konya Beyhekim Training and Research Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology